NYSE (USA) TSX (CANADA)

Directory of Stock Market Company

This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.

Search into NYSE and TSX
by quote, company name or key word

facebooktwitterlinkedin
Mail

NPC - Allon Therapeutics Inc

Allon Therapeutics Inc. (Allon) is a clinical-stage biotechnology company developing treatments for neurodegenerative conditions. Allon’s drug, davunetide, has demonstrated human efficacy in amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease (AD), and in cognitive impairment associated with schizophrenia (CIAS). Allon has advanced clinical development programs pursuing lar","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"

NPC Chart

Allon Therapeutics Inc News


New Allon research presented at leading scientific symposium
MarketWatch (press release) - May 14, 2012
VANCOUVER, May 14, 2012 /PRNewswire via COMTEX/ -- Allon Therapeutics Inc. (TOR:CA:NPC) announced today that a presentation given May 12 at the prestigious 12th International Stockholm / Springfield Symposium on Advances in Alzheimer Therapy featured ...

Allon Therapeutics releases first quarter 2012 operating results
4-traders - May 8, 2012
VANCOUVER, BC - Allon Therapeutics Inc.(TSX: NPC) today announced its unaudited operating results for the three months ended March 31, 2012 and updated clinical development plans for 2012.

Allon Therapeutics announces completion of $10 million private placement
MarketWatch (press release) - May 2, 2012
VANCOUVER, May 2, 2012 /PRNewswire via COMTEX/ -- Allon Therapeutics Inc. (TOR:CA:NPC) announced today that it has completed the previously announced brokered private placement equity offering resulting in gross proceeds of $10 million as more ...

Allon Therapeutics Inc Announces Completion Of $10 Million Private Placement
Reuters Key Development - May 2, 2012

Allon Therapeutics Inc. Announces Private Placement
Reuters Key Development - Apr 16, 2012

Allon Therapeutics Inc. Receives U.S. Patent For Neurotoxicity Caused By Anti-cancer Drugs
Reuters Key Development - Mar 28, 2012

Allon Therapeutics Inc. Secures $2.5 Million Bridge Financing
Reuters Key Development - Mar 9, 2012

Allon Therapeutics Inc. Secures New Patent
Reuters Key Development - Mar 5, 2012

Allon Therapeutics Inc. Secures United States Patent
Reuters Key Development - Nov 30, 2011

Allon Therapeutics Inc. Completes Equity Offering
Reuters Key Development - Oct 18, 2011

TSX Media Coverage Selection of the best articles found in your favorit medias

Next Company >>